Two Sigma Securities’s ImmunityBio IBRX Stock Holding History

Two Sigma Securities’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-22,525	Closed	-$173K	–	2029
2026 Q1	$173K	Buy	+22,525	New	+$154K	0.02%	1079
2025 Q4	–	Sell	-22,860	Closed	-$56.2K	–	1725
2025 Q3	$56.2K	Buy	22,860 +10,538	+86%	+$27.1K	0.01%	971
2025 Q2	$32.5K	Buy	+12,322	New	+$33.1K	﹤0.01%	1145
2024 Q1	–	Sell	-43,604	Closed	-$219K	–	3247
2023 Q4	$219K	Buy	43,604 +9,624	+28%	+$30.2K	﹤0.01%	2313
2023 Q3	$57.4K	Buy	+33,980	New	+$68.2K	﹤0.01%	2454
2023 Q2	–	Sell	-11,678	Closed	-$21.3K	–	3042
2023 Q1	$21.3K	Buy	+11,678	New	+$36.3K	﹤0.01%	2354
2022 Q2	–	Sell	-40,502	Closed	-$227K	–	2505
2022 Q1	$227K	Buy	+40,502	New	+$248K	0.01%	1644
2019 Q3	–	Sell	-12,175	Closed	-$12K	–	2231
2019 Q2	$12K	Buy	12,175 +227	+2%	+$262	﹤0.01%	1980
2019 Q1	$19K	Buy	+11,948	New	+$15K	﹤0.01%	1674

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Securities's IBRX Position: Q2 2026 in Review

Two Sigma Securities sold out of ImmunityBio (IBRX) in Q2 2026, closing a stake of 22,525 shares — an estimated $173K sold.

Two Sigma Securities first reported a position in IBRX in Q1 2019 and held it in 9 quarters. The position peaked at $227K in Q1 2022. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Two Sigma Securities reported no remaining ImmunityBio position as of Q2 2026 after selling out during the quarter.
Two Sigma Securities sold 22,525 ImmunityBio shares in Q2 2026, an estimated $173K.
Two Sigma Securities first reported a position in ImmunityBio in Q1 2019 and held it in 9 quarters.
Two Sigma Securities's ImmunityBio position peaked at $227K in Q1 2022.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.